NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, the ATCs faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - Following the announcement of poor financial results, Iovance's stock price fell over 44%, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided dividends to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction [3]. - On May 1, 2025, Organon announced a drastic cut in its dividend payout from $0.28 per share to $0.02 per share, leading to a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (NYSE: RDDT) for potential violations of the federal securities laws. If you invested in Reddit, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action. Why is Reddit being Investigated? Reddit owns and operates the eponymous social news aggregation, forum, and social med ...

Group 1 - The article discusses the importance of in-depth research on various income alternatives such as REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs [1] - It highlights the popularity of the service, evidenced by 438 testimonials, most of which are rated 5 stars [1] Group 2 - The article does not provide specific investment recommendations or advice, emphasizing that past performance does not guarantee future results [2] - It clarifies that the analysts contributing to the platform may not be licensed or certified by any regulatory body [2]

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Oracle. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Core Insights - The article emphasizes the importance of conducting thorough due diligence before making any investment decisions [2][3] - It highlights that past performance does not guarantee future results, indicating a need for cautious evaluation of investment opportunities [3] Group 1 - The article serves solely for informational purposes and is not intended as investment advice [2] - It stresses that the author does not have any business relationships with the companies mentioned, ensuring an unbiased perspective [2] - The content is produced by third-party authors, which may include both professional and individual investors without formal licensing [3] Group 2 - The article notes that future outcomes are uncertain and can change based on evolving market conditions [2] - It advises investors to seek personal financial advice for specific investment decisions [2] - The information provided is meant to assist in the due diligence process rather than serve as a direct recommendation [2]

Group 1: Chevron (CVX) - Chevron's stock has declined by 23% from its all-time high in January 2023, which correlates with a 22% dip in the price of oil benchmark West Texas Intermediate during the same period [4][5] - The company has a strong track record of increasing dividends for 38 consecutive years, with a conservative average payout ratio of 68.4% over the past five years [5] - Chevron operates across the entire energy value chain, allowing it to benefit from greater efficiencies and mitigate risks associated with any single segment of the energy business [6] Group 2: Vertiv (VRT) - Vertiv's stock is down approximately 26% from its all-time high, but it has shown significant recovery recently, making it a potential buying opportunity [8] - The company is positioned to benefit from ongoing investments in artificial intelligence (AI) and data centers, with no signs of a slowdown in data center spending [9] - Vertiv's new 800-volt high voltage direct current (HVDC) power systems are expected to be ready by the second half of 2026, aligning with Nvidia's platform rollouts in 2027, which could drive a new cycle of orders [11]

Group 1 - Esperion Therapeutics, Inc (NASDAQ: ESPR) has experienced a 64% rebound from its all-time low, indicating positive market response amidst recent biotech and healthcare conferences [1] - The company has been actively participating in various industry conferences, which may have contributed to the stock's recovery [1] Group 2 - The article highlights the author's extensive background in financial markets, including experiences during significant market events, which may provide valuable insights into investment strategies [1] - The author emphasizes the importance of both technical and fundamental analysis in trading and investing, suggesting a comprehensive approach to market evaluation [1]